Examining B7-H3: An Emerging Therapeutic Target for Solid Tumors
Examining B7-H3: An Emerging Therapeutic Target for Solid Tumors is organized by Prime Education, LLC.
Release Date: August 18, 2023
Expiration Date: December 7, 2024
Description:
Explore the emerging field of B7-H3 therapeutic targeting in solid tumor malignancies. This concise and convenient booster quiz educational module is designed to test your knowledge on the underlying mechanisms and new clinical data related to B7-H3 as a potential target for novel anticancer therapies to stay on the cutting edge of the latest treatment advancements. This unique learning experience provides:
• Instant expert feedback on your answer selections
• opportunity to see how well you do relative to your peers
• Access to downloadable evidence with relevant clinical practice tips
Learning Objectives:
• Describe the role of B7-H3 in normal and tumor tissues and as a novel target for anti-cancer therapies
• Differentiate the mechanisms of emerging B7-H3-directed therapies
• Evaluate the latest clinical safety and efficacy data on B7-H3-directed immunotherapies
Agenda:
• The Role of B7-H3 in Normal and Tumor Tissues
• Mechanisms of Emerging B7-H3-Directed Therapies
• Clinical Safety and Efficacy Data for B7-H3-Directed Immunotherapies